Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6401 to 6450 of 8915 results

  1. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued Reference number: GID-TA10490

    Technology appraisal guidance
    Discontinued

  2. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued Reference number: GID-TA10492

    Technology appraisal guidance
    Discontinued

  3. Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

    Discontinued Reference number: GID-TA10494

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued Reference number: GID-TA10495

    Technology appraisal guidance
    Discontinued

  5. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

    Discontinued Reference number: GID-TA10512

    Technology appraisal guidance
    Discontinued

  7. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued Reference number: GID-TA10522

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued Reference number: GID-TA10228

    Technology appraisal guidance
    Discontinued

  9. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  11. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued Reference number: GID-TA10236

    Technology appraisal guidance
    Discontinued

  12. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued Reference number: GID-TA10242

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  15. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  16. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

    Technology appraisal guidance
    Discontinued

  17. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development Reference number: GID-TA10261 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued Reference number: GID-TA10264

    Technology appraisal guidance
    Discontinued

  19. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  20. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  21. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued Reference number: GID-TA10284

    Technology appraisal guidance
    Discontinued

  22. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued Reference number: GID-TA10297

    Technology appraisal guidance
    Discontinued

  23. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued Reference number: GID-TA10830

    Technology appraisal guidance
    Discontinued

  24. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  25. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued Reference number: GID-TA10857

    Technology appraisal guidance
    Discontinued

  26. Tisagenlecleucel for treating relapsed or refractory aggressive diffuse large B-cell lymphoma after 1 systemic therapy [ID3974]

    Discontinued Reference number: GID-TA10859

    Technology appraisal guidance
    Discontinued

  27. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued Reference number: GID-TA10870

    Technology appraisal guidance
    Discontinued

  28. Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

    Discontinued Reference number: GID-TA10875

    Technology appraisal guidance
    Discontinued

  29. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development Reference number: GID-TA10882 Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued Reference number: GID-TA10891

    Technology appraisal guidance
    Discontinued

  32. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued Reference number: GID-TA10892

    Technology appraisal guidance
    Discontinued

  33. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  36. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

    Technology appraisal guidance
    Discontinued

  37. Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

    Discontinued Reference number: GID-TA10934

    Technology appraisal guidance
    Discontinued

  38. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued Reference number: GID-TA10963

    Technology appraisal guidance
    Discontinued

  40. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued Reference number: GID-TA10970

    Technology appraisal guidance
    Discontinued

  41. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development Reference number: GID-TA11010 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  43. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued Reference number: GID-TA10628

    Technology appraisal guidance
    Discontinued

  44. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued Reference number: GID-TA10631

    Technology appraisal guidance
    Discontinued

  45. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued Reference number: GID-TA10633

    Technology appraisal guidance
    Discontinued

  46. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued Reference number: GID-TA10634

    Technology appraisal guidance
    Discontinued

  47. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued Reference number: GID-TA10635

    Technology appraisal guidance
    Discontinued

  48. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued Reference number: GID-TA10637

    Technology appraisal guidance
    Discontinued

  49. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

    Technology appraisal guidance
    Discontinued

  50. Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

    In development Reference number: GID-TA10667 Expected publication date: TBC

    Technology appraisal guidance
    In development